Arsanis designs monoclonal antibodies (mAbs) to address the unique features and virulence mechanisms of each targeted pathogen. To do so, we use multiple discovery approaches, combining our expertise in bacterial and viral pathogenesis, protein engineering and immunology, as well as our knowledge of preclinical and clinical development of anti-infective agents, and partnerships that provide access to leading scientific and discovery platforms.
We prioritize target selection for each of our programs based upon numerous factors, including unmet medical need, multi-drug resistant pathogens, diseases with significant morbidity and mortality, and the ability to address these needs via antibody-based approaches.
While other mAbs in development focus on single targets, Arsanis sets out to address the unique underlying biology of the selected pathogen for each of our programs. To address certain pathogens successfully, our mAbs must target all of the relevant biological targets that contribute to disease, ensuring a comprehensive approach to interrupting pathogenesis. For example, ASN100 targets six individual cytotoxins produced by Staphylococcus aureus that are critical to pneumonia pathogenesis.